Their study showed that AXL induced RAD18 expression in EGFR-TKI-treated NSCLC cells; hence, low-fidelity replication accelerates mutagenesis, which confers acquired resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.